Allen Bowling
Englewood, CONPI 1790778744
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $511,110 of the $637,542 with a category attached, or 80.2%. 20 manufacturers reported payments, led by EMD Serono, Inc. at 47.1% of the total. Reporting peaked in 2019 at $205,234 and has fallen 100.0% since, to $63 in 2025.
Across 743 payments — averaging $858.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$301K
- Sanofi$136K
- Biogen$48K
- Genentech USA, Inc.$43K
- Bristol Myers Squibb$28K
- E.r. Squibb & Sons, L.L.C.$21K
- plus $61K from 14 others
Across 25 payments — averaging $2832.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$51K
- EMD Serono, Inc.$20K
What the payments were for
- Consulting fees$66,01310%
- Speaking & faculty fees$511,11080%
- Travel & lodging$50,3518%
- Food & beverage$9,7392%
- Education$3280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 303 | $300,576 |
| Sanofi | 161 | $135,667 |
| Biogen | 79 | $47,905 |
| Genentech USA, Inc. | 34 | $43,237 |
| Bristol Myers Squibb | 57 | $27,617 |
| E.r. Squibb & Sons, L.L.C. | 13 | $21,373 |
| Johnson & Johnson | 20 | $19,213 |
| Novartis | 20 | $13,370 |
| TG Therapeutics, Inc. | 25 | $13,241 |
| Banner Life Sciences, LLC | 3 | $5,658 |
| AstraZeneca | 8 | $4,257 |
| Mallinckrodt Hospital Products Inc. | 5 | $2,279 |
| Janssen Scientific Affairs, LLC | 1 | $1,320 |
| Janssen Global Services, LLC | 1 | $1,320 |
| Amgen | 3 | $286 |
| Mallinckrodt Enterprises LLC | 3 | $79 |
| AbbVie | 3 | $63 |
| Acorda Therapeutics, Inc | 2 | $43 |
| Bioventus LLC | 1 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 14 | $80,621 |
| Glatiramer Acetate | 14 | $34,812 |
| Teriflunomide | 26 | $14,498 |
| Dalfampridine ErDalfampridine | 30 | $8,490 |
| Baclofen | 36 | $1,633 |
| Gabapentin | 17 | $925 |
| Escitalopram Oxalate | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.